SEC Form 4 · accession 0001193125-26-387924
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine Zimmermann
Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 4:24 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001841387
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.60 | Sep 8, 2026 | A | 64,000 | A | — | Sep 8, 2036 | Common Stock | 64,000 | 64,000 | D |
Explanation of responses
- F1The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.